Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)
(2024)
Journal Article
Vasudev, N. S., Ainsworth, G., Brown, S., Pickering, L., Waddell, T., Fife, K., Griffiths, R., Sharma, A., Katona, E., Howard, H., Velikova, G., Maraveyas, A., Brown, J., Pezaro, C., Tuthill, M., Boleti, E., Bahl, A., Szabados, B., Banks, R. E., Brown, J., …Powles, T. (2024). Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM). Journal of Clinical Oncology, 42(3), 312-323. https://doi.org/10.1200/JCO.23.00236
PURPOSE: Ipilimumab (IPI), in combination with nivolumab (NIVO), is an approved frontline treatment option for patients with intermediate- or poor-risk advanced renal cell carcinoma (aRCC). We conducted a randomized phase II trial to evaluate whether... Read More about Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM).